ALKS
Price
$30.26
Change
-$0.54 (-1.75%)
Updated
Oct 17 closing price
Capitalization
5B
4 days until earnings call
Intraday Buy/Sell Signals
VTRS
Price
$10.17
Change
+$0.07 (+0.69%)
Updated
Oct 17 closing price
Capitalization
11.86B
19 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

ALKS vs VTRS

Header iconALKS vs VTRS Comparison
Open Charts ALKS vs VTRSBanner chart's image
Alkermes
Price$30.26
Change-$0.54 (-1.75%)
Volume$2.04M
Capitalization5B
Viatris
Price$10.17
Change+$0.07 (+0.69%)
Volume$5.51M
Capitalization11.86B
ALKS vs VTRS Comparison Chart in %
ALKS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VTRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALKS vs. VTRS commentary
Oct 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALKS is a Hold and VTRS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 18, 2025
Stock price -- (ALKS: $30.26 vs. VTRS: $10.17)
Brand notoriety: ALKS and VTRS are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ALKS: 107% vs. VTRS: 60%
Market capitalization -- ALKS: $5B vs. VTRS: $11.86B
ALKS [@Pharmaceuticals: Generic] is valued at $5B. VTRS’s [@Pharmaceuticals: Generic] market capitalization is $11.86B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.85B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.93B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALKS’s FA Score shows that 2 FA rating(s) are green whileVTRS’s FA Score has 2 green FA rating(s).

  • ALKS’s FA Score: 2 green, 3 red.
  • VTRS’s FA Score: 2 green, 3 red.
According to our system of comparison, both ALKS and VTRS are a good buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALKS’s TA Score shows that 5 TA indicator(s) are bullish while VTRS’s TA Score has 5 bullish TA indicator(s).

  • ALKS’s TA Score: 5 bullish, 5 bearish.
  • VTRS’s TA Score: 5 bullish, 6 bearish.
According to our system of comparison, ALKS is a better buy in the short-term than VTRS.

Price Growth

ALKS (@Pharmaceuticals: Generic) experienced а -3.04% price change this week, while VTRS (@Pharmaceuticals: Generic) price change was +4.41% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.79%. For the same industry, the average monthly price growth was +4.23%, and the average quarterly price growth was +51.45%.

Reported Earning Dates

ALKS is expected to report earnings on Oct 22, 2025.

VTRS is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.79% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VTRS($11.9B) has a higher market cap than ALKS($5B). VTRS has higher P/E ratio than ALKS: VTRS (236.20) vs ALKS (14.62). ALKS YTD gains are higher at: 5.216 vs. VTRS (-15.148). ALKS has higher annual earnings (EBITDA): 450M vs. VTRS (-493.3M). ALKS has more cash in the bank: 1.02B vs. VTRS (809M). ALKS has less debt than VTRS: ALKS (72.7M) vs VTRS (14.8B). VTRS has higher revenues than ALKS: VTRS (14.1B) vs ALKS (1.51B).
ALKSVTRSALKS / VTRS
Capitalization5B11.9B42%
EBITDA450M-493.3M-91%
Gain YTD5.216-15.148-34%
P/E Ratio14.62236.206%
Revenue1.51B14.1B11%
Total Cash1.02B809M126%
Total Debt72.7M14.8B0%
FUNDAMENTALS RATINGS
ALKS vs VTRS: Fundamental Ratings
ALKS
VTRS
OUTLOOK RATING
1..100
6827
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
12
Undervalued
PROFIT vs RISK RATING
1..100
31100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4448
P/E GROWTH RATING
1..100
211
SEASONALITY SCORE
1..100
9085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VTRS's Valuation (12) in the null industry is significantly better than the same rating for ALKS (97) in the Biotechnology industry. This means that VTRS’s stock grew significantly faster than ALKS’s over the last 12 months.

ALKS's Profit vs Risk Rating (31) in the Biotechnology industry is significantly better than the same rating for VTRS (100) in the null industry. This means that ALKS’s stock grew significantly faster than VTRS’s over the last 12 months.

ALKS's SMR Rating (100) in the Biotechnology industry is in the same range as VTRS (100) in the null industry. This means that ALKS’s stock grew similarly to VTRS’s over the last 12 months.

ALKS's Price Growth Rating (44) in the Biotechnology industry is in the same range as VTRS (48) in the null industry. This means that ALKS’s stock grew similarly to VTRS’s over the last 12 months.

VTRS's P/E Growth Rating (1) in the null industry is in the same range as ALKS (21) in the Biotechnology industry. This means that VTRS’s stock grew similarly to ALKS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALKSVTRS
RSI
ODDS (%)
Bearish Trend 2 days ago
59%
Bullish Trend 2 days ago
76%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
63%
Bearish Trend 2 days ago
59%
Momentum
ODDS (%)
Bearish Trend 2 days ago
68%
Bearish Trend 2 days ago
60%
MACD
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
65%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
63%
Bullish Trend 2 days ago
64%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
60%
Advances
ODDS (%)
Bullish Trend 16 days ago
76%
Bullish Trend 2 days ago
68%
Declines
ODDS (%)
Bearish Trend 8 days ago
62%
Bearish Trend 25 days ago
65%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
59%
Bearish Trend 2 days ago
66%
Aroon
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
58%
View a ticker or compare two or three
Interact to see
Advertisement
ALKS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VTRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EPLDX23.380.12
+0.52%
NYLI Epoch U.S. Equity Yield Class R6
BTLKX9.34N/A
N/A
Baillie Gifford Intl Concntr Gr EqsK
VFWSX142.13N/A
N/A
Vanguard FTSE All-Wld ex-US Idx Instl
PMEGX61.86N/A
N/A
T. Rowe Price Instl Mid-Cap Equity Gr
INAAX16.92N/A
N/A
Kotak India Equity Fund Class A

VTRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, VTRS has been loosely correlated with ELAN. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if VTRS jumps, then ELAN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VTRS
1D Price
Change %
VTRS100%
+0.69%
ELAN - VTRS
54%
Loosely correlated
+4.39%
ZTS - VTRS
47%
Loosely correlated
+0.56%
AMRX - VTRS
45%
Loosely correlated
+0.51%
EBS - VTRS
40%
Loosely correlated
-2.55%
COLL - VTRS
39%
Loosely correlated
+2.20%
More